Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 9Emgality

02 1Emgality/Rayvow

PharmaCompass

01

Brand Name : Emgality

Galcanezumab

arrow
Indo Livestock Expo
Not Confirmed

Brand Name : Emgality

arrow
Indo Livestock Expo
Not Confirmed

Galcanezumab

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 363

2019 Revenue in Millions : 163

Growth (%) : 123

blank

02

Brand Name : Emgality

Galcanezumab

arrow
Indo Livestock Expo
Not Confirmed

Brand Name : Emgality

arrow
Indo Livestock Expo
Not Confirmed

Galcanezumab

Main Therapeutic Indication : Neurology

Currency : USD

2021 Revenue in Millions : 577

2020 Revenue in Millions : 363

Growth (%) : 59

blank

03

Brand Name : Emgality

Galcanezumab

arrow
Indo Livestock Expo
Not Confirmed

Brand Name : Emgality

arrow
Indo Livestock Expo
Not Confirmed

Galcanezumab

Main Therapeutic Indication : Neurology

Currency : USD

2022 Revenue in Millions : 651

2021 Revenue in Millions : 577

Growth (%) : 13

blank

04

Brand Name : Emgality

Galcanezumab

arrow
Indo Livestock Expo
Not Confirmed

Brand Name : Emgality

arrow
Indo Livestock Expo
Not Confirmed

Galcanezumab

Main Therapeutic Indication : Neurology

Currency : USD

2022 Revenue in Millions : 45

2021 Revenue in Millions : 39

Growth (%) : 17

blank

05

Brand Name : Emgality

Galcanezumab

arrow
Indo Livestock Expo
Not Confirmed

Brand Name : Emgality

arrow
Indo Livestock Expo
Not Confirmed

Galcanezumab

Main Therapeutic Indication : Neurology

Currency : USD

2023 Revenue in Millions : 678

2022 Revenue in Millions : 651

Growth (%) : 4

blank

06

Brand Name : Emgality

Galcanezumab

arrow
Indo Livestock Expo
Not Confirmed

Brand Name : Emgality

arrow
Indo Livestock Expo
Not Confirmed

Galcanezumab

Main Therapeutic Indication : Neurology

Currency : USD

2023 Revenue in Millions : 49

2022 Revenue in Millions : 45

Growth (%) : 22

blank

07

Brand Name : Emgality/Rayvow

Galcanezumab/Lasmiditan

arrow
Indo Livestock Expo
Not Confirmed

Brand Name : Emgality/Rayvow

arrow
Indo Livestock Expo
Not Confirmed

Galcanezumab/Lasmiditan

Main Therapeutic Indication : Neurology

Currency : USD

2024 Revenue in Millions : 107

2023 Revenue in Millions : 0

Growth (%) : NA

blank

08

Brand Name : Emgality

Galcanezumab

arrow
Indo Livestock Expo
Not Confirmed

Brand Name : Emgality

arrow
Indo Livestock Expo
Not Confirmed

Galcanezumab

Main Therapeutic Indication : Neurology

Currency : USD

2024 Revenue in Millions : 13

2023 Revenue in Millions : 48

Growth (%) : -73

blank

09

Brand Name : Emgality

Galcanezumab

arrow
Indo Livestock Expo
Not Confirmed

Brand Name : Emgality

arrow
Indo Livestock Expo
Not Confirmed

Galcanezumab

Main Therapeutic Indication : Neurology

Currency : USD

2024 Revenue in Millions : 870

2023 Revenue in Millions : 678

Growth (%) : 28

blank

10

Brand Name : Emgality

Galcanezumab

arrow
Indo Livestock Expo
Not Confirmed

Brand Name : Emgality

arrow
Indo Livestock Expo
Not Confirmed

Galcanezumab

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2019 Revenue in Millions : 163

2018 Revenue in Millions : 5

Growth (%) : 3,216

blank